巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    CRISPR Therapeutics AG

    CRSP
    56.400
    0.130
    0.23%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・CRISPR Therapeutics AG - 延遲價格・最後更新於 20/05 12:15
    最高位
    58.040
    最低位
    52.730
    開市價
    --
    前收市價
    56.530
    成交量(千)
    128.77
    成交額(百萬)
    64.69
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    4,368.58
    市盈率
    14.500
    息率
    --
    差價
    --
    52週高低
    169.760 - 42.511
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    CRISPR Therapeutics AG
    證券代碼
    CRSP.US
    所屬板塊
    Biotechnology
    公司業務
    CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    發行量
    77067587
    公司總部
    Baarerstrasse 14
    公司網址
    http://www.crisprtx.com
    公司電郵
    susan.kim@crisprtx.com
    公司電話
    +41 415613277

    抄錯底?ARK大舉加倉基因編輯公司大跌 更多對沖基金提前埋伏

    佟岷·
    抄錯底?ARK大舉加倉基因編輯公司大跌 更多對沖基金提前埋伏

    關於

    CRISPR Therapeutics AG(CRSP.US)所屬的行業板塊為Biotechnology。
    CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
    詳細公司背景可參考: http://www.crisprtx.com